ligustilide and Dementia--Vascular

ligustilide has been researched along with Dementia--Vascular* in 1 studies

Other Studies

1 other study(ies) available for ligustilide and Dementia--Vascular

ArticleYear
Ligustilide ameliorates cognitive impairment via AMPK/SIRT1 pathway in vascular dementia rat.
    Metabolic brain disease, 2022, Volume: 37, Issue:5

    Vascular dementia (VaD) is the second cause of dementia after Alzheimer's disease. Ligustilide (LIG) is one of the main active ingredients of traditional Chinese medicines, such as Angelica. Studies have reported that LIG could protect against VaD. However, the mechanism is still confused. In this study, we employed a bilateral common carotid artery occlusion rat model to study. LIG (20 or 40 mg/kg/day) and Nimodipine (20 mg/kg) were orally administered to the VaD rats for four weeks. Morris water maze test showed that LIG effectively ameliorated learning and memory impairment in VaD rats. LIG obviously reduced neuronal oxidative stress damage and the level of homocysteine in the brain of VaD rats. Western blot results showed that pro-apoptotic protein Bax and cleaved caspase 3 increased and anti-apoptotic protein Bcl-2 decreased in the hippocampi of VaD rats. But after LIG treatment, these changes were reversed. Moreover, Nissl staining result showed that LIG could reduce neuronal degeneration in VaD rats. Furthermore, LIG enhanced the expressions of P-AMPK and Sirtuin1(SIRT1) in VaD rats. In conclusion, these studies indicated that LIG could ameliorate cognitive impairment in VaD rats, which might be related to AMPK/SIRT1 pathway activation.

    Topics: 4-Butyrolactone; AMP-Activated Protein Kinases; Animals; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; Maze Learning; Rats; Sirtuin 1

2022